The ethics of randomized placebo controlled trials of antidepressants with pregnant women

International Journal of Risk and Safety in Medicine

Volumn 22, Issue 1, 2010, Pages 7-16

  Healy, David ^a   Mangin, Derelie ^b   Mintzes, Barbara ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antidepressants; Birth defects; Ghost writing; Miscarriage; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL HEART MALFORMATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; ELECTROCONVULSIVE THERAPY; FETUS MONITORING; HUMAN; MAJOR DEPRESSION; MEDICAL ETHICS; MOTHER CHILD RELATION; PREGNANCY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SUICIDE; TERATOGENESIS;

EID: 77949557801     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: 10.3233/JRS-2010-0487     Document Type: Review

References (54)

1. L.L. Altschuler, L. Cohen, M.P. Szuba, V.K. Burt, M. Gitlin and J. Mintz, Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines, American J Psychiatry 153 (1996), 592-606.
2. S. Alwan, J. Reefhuis, O. Rasmussen, R. Olney and J. Friedman, Use of selective serotonin reuptake inhibitors in pregnancy and the risk of birth defects, New England J Med 356 (2007), 2684-2692.
3. M. Bakker, S.Kerstjens-Frederikse, M.Van den Berg, L. De Jong-Van den Berg and H. DeWalle, Use of selective serontonin reuptake inhibitors in early pregnancy and risk of cardiac malformations, Pharmacoepidemiol Drug Saf 15 (2006), S81.
4. A. Berard, E. Ramos, E. Rey, L. Blais, M. St-Andre and D. Oraichi, First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage, Birth Defects Research 80 (2006), 18-27.
5. L. Bonari, N. Pinto, E. Ahn, A. Einarson, M. Steiner and G.Koren, Perinatal risks of untreated depression during pregnancy, Can J Psychiatry 49 (2004), 726-735.
6. I.F. Brockington, Motherhood and Mental Illness, Oxford University Press, Oxford, 1996.
7. R.C. Casper, B.E. Fleisher, J.C. Lee-Ancajas, A. Gilles, E. Gaylor, A. DeBattist and E. Hoyme, Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy, J Pediatr 142 (2003), 402-408.
8. C.D. Chambers, S. Hernandez-Diaz, L.J. Van Marter, M.M. Werler, C. Louik, K.L. Jones and A.A. Mitchell, Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn, N Engl J Med 354 (2006), 579-587.
9. L.S. Cohen, L.L. Altshuler, B.L. Harlow, R. Nonacs, D.J. Newport, A.C. Viguera, et al., Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment, JAMA 295(5) (2006), 499-507.
10. J.A. Cole, S.A. Ephross, I.S. Cosmatos and A.M.Walker, Paroxetine in the first trimester and the prevalence of congenital malformations, Pharmacoepidemiology and Drug Safety 16 (2007), 1075-1085.
11. J.H. Coverdale, L.B. McCullagh and F.A. Chervenak, The ethics of randomized placebo controlled trials of antidepressants with pregnancy women: a systematic review, Obstetrics and Gynecology 112 (2008), 1361-1368.
12. M.L. Dahl, E. Olhager and J. Ahlner, Paroxetine withdrawal in a neonate, British J Psychiatry 171 (1997), 391-394.
13. R. Davis, D. Rubanowice, H. McPhillips, M. Raebel, S. Andrade, D. Smith, M. Ulcickas Yood and R. Platt, Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy, Pharmacoepidemiol Drug Saf 16 (2007), 1086-1096.
14. O. Diav-Citrin, S. Shechtman, D.Weinbaum, J. Arnon, R.Weinberg and A. Ornoy, Pregnancy outcome following gestational exposure to paroxetine: a prospective controlled cohort study, Teratology Society Abstracts (2002), DOI 101002/tera.10073, p. 298, abstract 13.
15. O. Diav-Citrin, S. Shechtman, D. Weinbaum, R. Wajnberg, M. Avgil, E. De Gianantonio, M. Clementi, C. Weber- Schoendorfer, C. Schaefer and A. Ornoy, Paroxetine and fluoxetine in pregnancy: a prospective multicentre, controlled observational study, Br J Clin Pharmacology 66 (2008), 695-705.
16. E. Eggermont, J. Reveschot, V. Deneve and M. Casteels-Van Daele, The adverse influence of imipramine on the adaptation of the newborn infant to extrauterine life, Acta Paediatrica Belgica 26 (1972), 197-204.
17. D.M. Fergusson, L.J. Horwood and M.T. Lynskey, Early dentine lead levels and educational outcomes at 18 years, J Child Psychology & Psychiatry & Allied Disciplines 38 (1997), 471-478.
18. N.I. Gavin, B.N. Gaynes, K.N. Lohr, S. Meltzer-Brody and G.Y.S. Gartlehner, Perinatal depression: a systematic review of prevalence and incidence, Obstet Gynecol 106(5 Pt 1) (2005), 1071-1083.
19. D. Healy, The antidepressant tale: figures signifying nothing? Advances in Psychiatric Treatment 12 (2006), 320-328.
20. M.E. Hemels, A. Einarson, G. Koren, K.L. Lanctot and T.R. Einarson, Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis, Am Pharmacother 39 (2005), 803-809.
21. V. Hendrick, L.M. Smith, R. Suri, S. Hwang, D. Haynes and L. Altshuler, Birth outcomes after prenatal exposure to antidepressant medication, Am J Obstet Gynecol 188 (2003), 812-815.
22. L.J. Horwood and D.M. Fergusson, Breastfeeding and later cognitive and academic outcomes, Pediatrics 101(1) (1998), E9.
23. Grassley C.E., Letter to JamesWagner, President, Emory University, June 2nd 2009, from Senator CE Grassley, US Senate, http://s.wsj.net/public/ resources/documents/WSJ LttrEmoryUni 090609.pdf, 2009.
24. Incomplete financial disclosure, JAMA 296 (2006), 170. doi:10.1001/jama.296.2.170
25. B. Kallen and P.O. Olausson, Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations, Birth Defects Res A Clin Mol Teratol 79 (2007), 301-309.
26. N.A. Kulin, A. Pastuszak, S.R. Sage, B. Schick-Boschetto, G. Spivey, M. Feldkamp, K. Ormond, D. Matsui, A.K. Stein- Schechman, L. Cook, J. Brochu, M. Rieder and G. Koren, Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study, JAMA 279 (1998), 609-610.
27. J.M. Lauder, Neurotransmitters as growth regulatory signals: Role of receptors and second messengers, TINS 16 (1993), 233-240.
28. G. Lewis (ed.), The confidential enquiry into maternal and child health (CEMACH). Saving mothers' lives: reviewing maternal deaths to make motherhood safer - 2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. CEMACH, London, 2007.
29. C. Louik, A. Lin, M. Werler, S. Hernandez-Diaz and A. Mitchell, First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects, New England Journal of Medicine 356 (2007), 2675-2683.
30. H. Malm, T. Klaukka and P.J. Neuvonen, Risks associated with selective serotonin reuptake inhibitors in pregnancy, Obstetrics and Gynecology 106 (2005), 1289-1296.
31. P. Merlob, E. Birk, L. Sirota, N. Linder, M. Bevant, B. Stahl and G. Klinger, Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heard murmur, Birth Defects Research Part A, Clinical and Molecular Teratology 85 (2009), 837-841.
32. J. Milgrom, A.W. Gemmill, J.L. Bilszta, B. Hayes, B. Barnett, J. Brooks, et al., Antenatal risk factors for postnatal depression: a large prospective study, J Affect Dis 108(1-2) (2008), 147-157.
33. J.R.D. Moiseiwitsch and J.M. Lauder, Serotonin regulates mouse cranial neural crest migration, Proc Natl Acad Sci USA 92 (1995), 7182-7186.
34. C.M. Nash, C.M. O'Connell and A.A. Howlett, Neonatal outcomes associated with maternal antidepressant use in a population cohort of Nova Scotian pregnancies between 1993 and 2004, Paediatrics and Child Health 12 (SA) (2007), 42.
35. C.G. Nebigil, D.S. Choi, A. Dierich, P. Hickel, M. Le Meur, N. Messadeq, J.M. Launay and L. Maroteaux, Serotonin 2B receptor is required for heart development, Proc Nat Acad Sci 97 (2000), 9508-9513.
36. T.E. Oberlander, W. Warburton, S. Misri, W. Riggs, J. Aghajanian and C. Hertzman, Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population based health data, Birth Defects Research Part B: Developmental and Reproductive Toxicology 83 (2008), 68-76.
37. B.L. Parry, Assessing risk and benefit: to treat or not to treat major depression during pregnancy with antidepressant medication, Am J Psychiatry 166 (2009), 512-514.
38. L.H. Pedersen,T.B. Henriksen, M.Vestergaard, J. Olsen and B.H. Bech, Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study, BMJ 339 (2009), b3569.
39. Paroxetine across the lifespan, Psychopharmacology Bulletin 37(Suppl. 1) (2003).
40. R. Rahimi, S. Nikfar and M. Abdollahi, Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a metaanalysis of clinical trials, Reprod Toxicol 22 (2006), 571-575.
41. E.J. Sanz, C. De-las-Cuevas, A. Kiuru, A. Bate and R. Edwards, Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis, Lancet 365 (2005), 482-487.
42. S. Schloemp,W.E. Paulus, K. Sterzik and F. Stoz, Congenital malformations after antidepressant medication with paroxetine in early pregnancy? Human Reproduction 21(Suppl. 1) (2006), i12.
43. D.L. Shuey, T.W. Sadler and J.M. Lauder, Serotonin as regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors, Teratology 46 (1992), 367-378.
44. G.E. Simon, M.L. Cunningham and R.L. Davis, Outcomes of prenatal antidepressant exposure, Am J Psychiatry 159 (2002), 2055-2061.
45. W.N. Sloot, H.C. Bowden and T.D. Yih, In vitro and in vivo reproduction toxicology of 12 monoaminergic reuptake inhibitors: Possible mechanisms of infrequent cardiovascular anomalies, Reproductive Toxicology (2008), doi:10.1016/j.reprotox.2009.04.005
46. M. Stone and L. Jones, Clinical review: relationship between antidepressant drugs and adult suicidality, Tables 16 and 18. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm, 2006.
47. C.L. Unfred, C.D. Chambers, R. Felix, K. Kao, L. Dick, S. Alvarado and K. Lyons-Jones, Birth outcomes among pregnant women taking paroxetine (Paxil). OTIS annual meeting, Teratology 63 (2001), 321-324.
48. T. Vial, M.P. Cournot, N. Bernard, P. Carlier, P. Jonville-Bera, M.J. Jean-Pastor, C. Bajhoux, E. Robert, E. Elefant and J. Descotes, Paroxetine and congenital malformations:Aprospective comparative study, Drug Saf 29(10) (2006), 911-1010.
49. S.W. Wen and M. Walker, The use of selective serotonin reuptake inhibitors in pregnancy, J Obstet Gynaecol Can 26 (2006), 819-822.
50. C.L. Wichman, K.M. Moore, T.R. Lang, J.L. St Sauver, R.H. Heise and W.J. Watson, Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy, Mayo Clinic Proceedings 84 (2009), 23-27.
51. K.L.Wisner, D.K. Sit and B.H. Hanusa, Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes, Am J Psychiatry 166 (2009), 557-566.
52. P. Wogelius, M. Norgaard, M. Gislum, L. Pedersen, E. Munk, P.B. Mortensen, L. Lipworth and H.T. Sorensen, Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations, Epidemiology 17 (2006), 701-704.
53. GlaxoSmithKline Clinical Studies Register. Epidemiology Study: First Trimester Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) and the risk of birth defects, www.gsk-clinicalstudyregister.com/files/pdf/24089.pdf
54. M.S. Yavarone, D.L. Shuey, H. Tamir, T.W. Sadler and J.M. Lauder, Serotonin and cardiac morphogenesis in the mouse embryo, Teratology 47 (1993), 573-584.